Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BOLT | US
-0.00
-0.31%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.64
0.65
0.66
0.60
Bolt Biotherapeutics Inc. a clinical-stage biotechnology company engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001 which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors including breast colorectal endometrial and gastroesophageal cancer. It is also developing BDC-2034 an agonist antibody targeting Dectin-2 for range of tumors such as head and neck non-small cell lung ovarian triple-negative breast and other cancer. The company has collaboration agreements with Toray Industries Genmab A/S Innovent Biologics Inc. Bristol-Myers Squibb and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics Inc. and changed its name to Bolt Biotherapeutics Inc. in July 2015. Bolt Biotherapeutics Inc. was incorporated in 2015 and is headquartered in Redwood City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
33.7%1 month
40.5%3 months
32.4%6 months
64.4%-
-
0.29
0.22
0.15
0.93
270.65
-
-72.23M
24.41M
24.41M
-
-1.49K
-
-11.00
-58.04
0.65
0.39
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.08
Range1M
0.14
Range3M
0.23
Rel. volume
1.37
Price X volume
125.47K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Akari Therapeutics Plc | AKTX | Biotechnology | 2.21 | 26.84M | -12.30% | n/a | -27.01% |
Common Stock | NRBO | Biotechnology | 3.16 | 26.82M | 6.76% | n/a | 0.90% |
PLUR | PLUR | Biotechnology | 4.8089 | 26.31M | -2.85% | n/a | 30845.83% |
SABS | SABS | Biotechnology | 2.76 | 25.47M | -11.25% | n/a | 11.58% |
Tonix Pharmaceuticals Holding Corp | TNXP | Biotechnology | 0.1794 | 25.11M | 12.83% | n/a | 21.99% |
Iterum Therapeutics plc | ITRM | Biotechnology | 1.09 | 24.75M | 5.83% | n/a | -198.11% |
iBio Inc | IBIO | Biotechnology | 2.85 | 24.62M | 0.00% | n/a | 20.92% |
CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 2.1301 | 24.58M | 2.41% | n/a | 3.98% |
Caladrius Biosciences Inc | LSTA | Biotechnology | 2.94 | 24.46M | 0.00% | n/a | 0.58% |
RenovoRx Inc. Common Stock | RNXT | Biotechnology | 1 | 23.99M | -1.46% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.93 | 0.53 | Expensive |
Ent. to Revenue | 270.65 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.29 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 32.42 | 72.92 | Lower Risk |
Debt to Equity | 0.22 | -1.24 | Expensive |
Debt to Assets | 0.15 | 0.25 | Cheaper |
Market Cap | 24.41M | 3.78B | Emerging |